Value proposition

We're changing the trajectory of human health, one baby at a time. Intent on a world without debilitating disease.

Infinant Health, Inc is a privately held company committed to changing the trajectory of human health, one baby at a time, through our deep understanding of infant nutrition and the gut microbiome. Years of proprietary research into the role of breast milk and its impact on human development led to our groundbreaking discovery of B. infantis EVC001, a natural bacterial strain foundational to infant immune health. Unfortunately, B. infantis had been almost completely eradicated from infants in developed countries due to unintended consequences of modern medicine such as feeding and birthing practices.

Now, there is a way to change that. What we found is that EVC001, our specific strain of B. infantis, is essential in developing a healthy microbiome and supporting healthy immune system function. We took that learning and developed INF108, a next-generation strain developed to prevent necrotizing enterocolitis (NEC) in pre-term infants.
We believe the greatest chance to impact future health begins early, right after birth—a once in a lifetime opportunity where rapid development and radical changes occur. By unlocking human nutrition's full potential through introducing beneficial bacteria during early infancy, we can help build a foundation for better health.
Investors in Infinant Health include Cargill and Bill & Melinda Gates Foundation, among others.

Infant Gut Microbiome, Pharmaceutical Development, Infant Health, Human Milk, Term/Preterm Infant Nutrition, Immune Development, Inflammation Control, Metagenomics, Machine Learning as a Medical Device (MLaMD), Software as a Medical Device (SaMD), Metabolomics, Drug Discovery, and Cognitive Development